Android Apple

Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint

By Yahoo! Finance   |   2 weeks ago
Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint

Zai Lab and Novocure reported positive results from the PANOVA-3 trial, showing improved overall survival in pancreatic cancer patients using TTFields therapy with chemotherapy. Plans for regulatory approval are underway, with Zai Lab focusing on China and Novocure aiming for global approval.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.